Skip to main content
All Posts By

Todd Levine MD

Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy

By Insights

A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders, Christopher Gibbons and Roy Freeman (and other academic colleagues), presented the first-ever data suggesting the possibility that measurable pathological markers in the skin can reveal distinct biological characteristics to help separate one type of synucleinopathy from another.

Read More

Researchers Detect Alpha-Synuclein in Nerve Biopsy 6 Years Before Clinical Diagnosis of Dementia With Lewy Bodies

By Insights

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.

Read More